2022 American Transplant Congress
Ultra-Short Duration Prophylaxis for Hepatitis C Donor Positive to Recipient Negative Simultaneous Kidney/Pancreas Transplants
Virginia Commonwealth University, Richmond, VA
*Purpose: Recent trials have successfully utilized a strategy of hepatitis C virus (HCV) D+ [Donor nucleic acid test (NAT) positive]/R- (Recipient NAT negative) kidney and/or…2022 American Transplant Congress
Use of Kidneys from Hepatitis C Nat Positive Donors for Uninfected Recipients: Early Results from a Rural Appalachian Kidney Transplant Program
*Purpose: Increasing mismatch between kidneys available for transplant and the number of patients on the transplant wait list has led to research into novel sources…2022 American Transplant Congress
Is Donor Hepatitis C Virus Infection Status Associated with Early Post-Kidney Transplant Failure in the Era of Direct-Acting Antiviral Medications?
*Purpose: To determine the influence of donor hepatitis C virus (HCV) infection status on early kidney transplant (KT) failure in HCV negative recipients in the…2022 American Transplant Congress
Outcomes in Hepatitis C (HCV) Viremic Grafts to HCV Negative Recipients in Heart Transplantation: A Multicenter Study of Differing Treatment Strategies
*Purpose: Using HCV viremic grafts for heart transplantation (HT) improves donor supply and shortens wait times. However, treatment strategies are variable post-transplant. This study aims…2022 American Transplant Congress
Is Stigma of Hepatitis C with KDPI Still Justified?
Comprehensive Transplant Center, The Ohio State University Wexner Medical Center, Columbus, OH
*Purpose: Kidney donor profile index (KDPI) is composed of 10 variables that are used to estimate the quality of a kidney. Hepatitis C virus (HCV)…2022 American Transplant Congress
Patient and Graft Survival for Simultaneous Kidney and Liver Transplant Recipients from Hepatitis C Viremic Donors: A Unos Database Analysis
General Surgery, Einstein Medical Center-Philadelphia, Philadelphia, PA
*Purpose: We aimed to compare recipient and graft survival for simultaneous kidney and liver transplant (SLK) recipients from hepatitis C virus (HCV) nucleic acid test…2022 American Transplant Congress
BK Polyomavirus and Cytomegalovirus Infections in Kidney Transplantation from Hepatitis C Positive Donors to Uninfected Recipients
Virginia Commonwealth University, Richmond, VA
*Purpose: Transplantation of hepatitis C viremic (HCV) donor kidneys into uninfected recipients (D+/R-) is becoming more common in the United States. However, the long-term risks…2022 American Transplant Congress
Current State of Use of Hepatitis C Viremic Donor Organs in Negative Recipients in the United States: A National Survey
*Purpose: Since the advent of direct-acting antiviral (DAA) therapy, use of hepatitis C (HCV) viremic donor organs in HCV negative recipients has become more common.…2022 American Transplant Congress
Eliminating Hepatitis C Positive Status from Kidney Donor Profile Index (KDPI) Calculations Results in Improved Transplant Rates and Outcomes in an Elderly Veteran Population
*Purpose: Overall mortality on the kidney transplant waiting list is higher for older patients. The average age of waitlisted veteran patients is 64, with patients…2022 American Transplant Congress
Expanded Experience with Ultra-Short Duration Pangenotypic Direct Acting Anti-Viral (DAA) Prophylaxis to Prevent Virus Transmission from Hepatitis C Viremic (HCV) Donors to Hepatitis C Negative Kidney Transplant Recipients (KT)
Virginia Commonwealth University, Richmond, VA
*Purpose: Previous studies have shown that HCV D+/R- kidney transplantation is feasible using 8-12 weeks of DAAs. Utilization of abbreviated regimens may obviate the need…
- 1
- 2
- 3
- …
- 28
- Next Page »